Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERESA: Stimulant Effects and Event Rate in ADHD
NCT01913912Phase 3Withdrawn
- Sponsor
- Ghent University
- Start
- Jan 2014
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Ghent University. Planned start Jan 2014; status: withdrawn.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01913912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01913912.